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We report on a female patient affected by galactosemia in whom the diagnosis was obscured by the concomitant
presence of manifestations suggesting a cow’s milk intolerance. This case exemplifies the problems in reaching a
correct diagnosis in patients with metabolic diseases.
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The metabolic diseases are a clinically heterogeneous
group of genetic disorders characterized by variable in-
volvement of multiple organs and systems. As the clinical
presentations of these disorders are often non-specific
and may mimic other diseases, it is not uncommon that
metabolic patients are not correctly recognized and that
there is a substantial delay between onset of clinical man-
ifestations and diagnosis. This is also due to the fact that
metabolic diseases are rare disorders, in some cases with
an extremely low prevalence, and are poorly known to
many physicians.
Here we present a case of galactosemia that exempli-
fies the difficulties in achieving a correct diagnosis when
clinical manifestations are overshadowed by concomitant
disorders.Case report
FB, a female, was born to non-consanguineous parents.
Her mother was affected by epilepsy and assumed
anticonvulsants (carbamazepine) throughout pregnancy.
She was born at 37 weeks of gestation. Delivery was
uneventful.
After birth she was fed with a standard formula. Jaun-
dice became evident in the first few days, with a total bili-
rubin of 15.5 mg/dl at 4 days, and was treated with
phototherapy. At 7 days she was referred to a neonatal* Correspondence: roberto.dellacasa@unina.it
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feeding, recurrent vomiting, and abdominal distention.
Routine biochemistry showed the presence of defective
coagulation (PT 27%), modest hypertransaminasemia
(AST 156 U/L; ALT 188 U/L), and a transient hyper-
ammonemia (202 mcrg/dl) that was not detected in
subsequent determinations. Biochemical analyses to de-
tect causes of infectious diseases were negative. Screen-
ings for metabolic disorders (blood gas analysis, plasma
acylcarnitine profile by tandem mass spectrometry,
plasma amino acids, urinary orotic acid and organic
acids, and a screening for congenital defects of glycosy-
lation) were all normal or non-informative. Brain, heart
and abdominal ultra-sound scans were normal. An oph-
thalmoscopy was also normal.
During the period in the intensive care unit she was
fed with a low-protein, lactose-free, hydrolysate formula
for 9 days, until the age of 16 days, with progressive clin-
ical improvement and complete recovery from the bio-
chemical abnormalities. This formula was chosen in the
hypothesis of a cow’s milk intolerance because of the
presence of vomiting. Considering the occasional detec-
tion of hyperammonemia, the daily protein intake was
restricted.
At the age of 16 days the hydrolysate formula was
interrupted and a standard formula feeding was re-intro-
duced, still with a reduced intake of proteins. Again,
vomiting and anorexia occurred, further supporting the
hypopthesis of cow’s milk intolerance. Thus, the same
protein hydrolysate formula used earlier was resumed
and continued in the following months.td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
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40 days, with a low-protein hydrolysate formula. At that
time routine biochemical analyses, including blood am-
monia and coagulation were normal.
She was referred to our Department at the age of
3 months and 20 days for further diagnostic work-up,
specifically focused on possible causes of hyperammone-
mia. During her stay at our Department all biochemical
analyses and screenings for metabolic disorders, includ-
ing urea cycle defects and other possible causes of
hyperammonemia, were normal or negative.
She was therefore discharged from our Department
with a protein hydrolysate formula, this time with a nor-
mal intake of proteins and calories, and followed with
periodic admissions to our Day-Hospital.
At the age of 8 months a formula containing cow’s
milk proteins was reintroduced. Once again, after
2 weeks the patient presented with anorexia and vomit-
ing and on a follow-up biochemical check-up hyper-
transaminasemia (AST 626 U/L; ALT 800 U/L),
hyperbilirubinemia (7.4 total; 3.4 conjugated), mild
hypoalbuminemia (3.6 g/dl), impaired coagulation (PT
31%; INR 2.6; aPTT 51.5 sec; fibrinogen 151; ATIII
157) were detected. At that time a Clinitest in urines
was positive, suggesting the diagnosis of galactosemia.
The diagnosis of galactosemia was confirmed by the
assay of galactose-1-phosphate uridyltransferase in
erythrocytes, showing a highly reduced activity (1.0
U/g Hb; normal values ≥ 2.3). The levels of galactose-
1-phosphate in erythrocytes were 9.40 mg/dl (vn: 0.00
– 0.24 mg/dl).
A lactose-free formula was started and continued for
the following months, with rapid and complete
normalization of the biochemical markers (AST 114 U/
L; ALT 316 U/L; total bilirubin 1.9 mg/dl, 0.82 conju-
gated; PT 93%; INR 1.06; aPTT 34.3 sec; fibrinogen 227;
ATIII 127).
Conclusions
This case emphasizes the importance of thinking to rare
metabolic disorders in the differential diagnosis of
patients presenting with relatively non-specific symp-
toms. Particular attention should be paid to the clinical
course and to its correlations with dietary changes. In
our patient the diagnosis of galactosemia was obscured
by the concomitant presence of manifestations suggest-
ing a cow’s milk intolerance.
Galactosemia is an inherited metabolic disorder, due
to the deficiency of the enzyme galactose-1-phosphate
uridyltransferase and with an estimated prevalence that
ranges between 1 in 30,000 and 1 in 60,000 births [1].
The clinical presentations is typically characterized by
severe liver involvement, that may progress to fatal liver
failure, but manifestations related to the involvement ofthe gastro-intestinal tract, such as those seen in our pa-
tient, are common. The occurrence of sepsis in un-
treated neonates, mainly due to E.coli, is also frequently
reported. Cataract is also a relatively frequent (14%)
finding in galactosemia [2]. The diagnosis is based on
the identification of clinical and biochemical manifesta-
tions of liver disease, on screening tests (clinitest in
urines, galactose-1-phosphate in erythrocytes), on the
biochemical assay that demonstrates the specific enzym-
atic defect in blood erythrocytes, and on the molecular
analysis of the GALT gene.
The treatment of galactosemia is based on the elimin-
ation of galactose and galactose-containing foods, that
results in complete recovery.
In our patient the presenting symptoms, particularly
gastro-intestinal signs such as vomiting on assumption
of standard formulas, and the clinical response to
repeated dietary changes initially supported the diagnosis
of cow’s milk intolerance, a very common disorder in in-
fancy. On the other hand the use of commercial protein
hydrolysate formulas, which are generally free from lac-
tose and galactose, prevented the occurrence of clinically
overt manifestations of the underlying metabolic disease,
until a standard formula was re-introduced at the age of
8 months.
Other factors also contributed to mask the manifesta-
tions of galactosemia. In the first few days the presence
of biochemical signs of liver disease were erroneously
attributed to the maternal use of antiepileptic drugs dur-
ing pregnancy. It is known that some antiepileptic drugs,
such as phenobarbital, fenitoin, carbamazepine, may
cross the placental barrier and induce microsomal
enzymes in fetal liver. An unexplained liver disease may
also be the sign of a broad range of distinct syndromes,
including familial hemophagocytosis [3] and complex
autoimmune disorders [4,5].
In addition, the absence in the first weeks of life of
lens opacities, a typical and peculiar finding in galactose-
mia, that may raise the suspect of galactosemia, contrib-
uted to the delay in achieving the correct diagnosis.
The clinical presentation of galactosemia is charac-
terized by relatively non-specific signs that may be
attributed to other disorders. This is a common find-
ing in many metabolic diseases that are characterized
in general by complex phenotypes, involving several
organs and systems, such as the central nervous sys-
tem [6,7], the respiratory tract [8-11], the gastro-
intestinal tract and liver [12-14], the muscolo-skeletal
system [15-18], and the immune system. Such a wide
variability and involvement of different systems may be
confusing in the diagnostic approach to patients with
metabolic disorders.
Simple and widely available screening tests, such as a
clinitest inurines, may be useful in patients that assume
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assay for newborn screening [19] would prevent mis-
diagnoses in patients affected by galactosemia. Unfortu-
nately a screening program for this disorder is not
available in all countries.
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